Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEONEC D19-01
2024-515603-19-00Phase 2Withdrawn
- Sponsor
- GERCOR
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide, carboplatin and cisplatin in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by GERCOR. Primary endpoints: 12-month relapse-free survival after neoadjuvant chemotherapy and 12-month relapse-free survival after surgery. Planned start Aug 2024; status: withdrawn.
02
Drugs
etoposidecarboplatincisplatin
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on 2024-515603-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515603-19-00.